Skip to main content

AstraZeneca Announces Updated Share Capital and Voting Rights

Tipranks - Tue Dec 2, 2025

TipRanks Cyber Monday Sale

An update from AstraZeneca ( (GB:AZN) ) is now available.

AstraZeneca PLC announced that as of November 30, 2025, its issued share capital with voting rights consists of 1,550,725,869 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s rules, which could impact shareholder engagement and transparency in the company’s governance.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on GB:AZN Stock

According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.

AstraZeneca’s strong financial performance and positive earnings call are the most significant factors driving the stock score. The technical analysis suggests potential short-term volatility due to overbought conditions, and the valuation indicates a relatively high price. Despite these concerns, the company’s strategic focus and growth potential support a favorable outlook.

To see Spark’s full report on GB:AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK. It specializes in the discovery, development, and commercialization of prescription medicines, focusing on Oncology, Rare Diseases, and BioPharmaceuticals, including areas such as Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are distributed in over 125 countries, serving millions of patients worldwide.

Average Trading Volume: 2,053,879

Technical Sentiment Signal: Buy

Current Market Cap: £216.6B

Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.